Assetmark Inc. Grows Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Assetmark Inc. raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 612.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 228 shares of the medical research company’s stock after purchasing an additional 196 shares during the period. Assetmark Inc.’s holdings in IQVIA were worth $54,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. First Foundation Advisors lifted its holdings in IQVIA by 3.8% in the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 43 shares in the last quarter. Invera Wealth Advisors LLC lifted its holdings in IQVIA by 0.3% in the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after purchasing an additional 46 shares in the last quarter. Covestor Ltd lifted its holdings in IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 48 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after purchasing an additional 48 shares in the last quarter. Finally, Continuum Advisory LLC increased its stake in shares of IQVIA by 3.3% during the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock valued at $325,000 after acquiring an additional 49 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of research analyst reports. BTIG Research dropped their price objective on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. TD Cowen dropped their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Finally, The Goldman Sachs Group dropped their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $259.13.

IQVIA Stock Down 0.8 %

Shares of NYSE:IQV opened at $191.19 on Tuesday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a 50 day moving average of $225.96 and a two-hundred day moving average of $228.02. The company has a market capitalization of $34.70 billion, a price-to-earnings ratio of 25.09, a price-to-earnings-growth ratio of 1.98 and a beta of 1.51.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This trade represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.